Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.

The modestly efficacious HIV-1 vaccine regimen (RV144) conferred 31% vaccine efficacy at 3 years following the four-shot immunization series, coupled with rapid waning of putative immune correlates of decreased infection risk. New strategies to increase magnitude and durability of protective immunit...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	LaTonya D Williams, Xiaoying Shen, Sheetal S Sawant, Siriwat Akapirat, Lindsay C Dahora, Matthew Zirui Tay, Sherry Stanfield-Oakley, Saintedym Wills, Derrick Goodman, DeAnna Tenney, Rachel L Spreng, Lu Zhang, Nicole L Yates, David C Montefiori, Michael A Eller, David Easterhoff, Thomas J Hope, Supachai Rerks-Ngarm, Punnee Pittisuttithum, Sorachai Nitayaphan, Jean-Louis Excler, Jerome H Kim, Nelson L Michael, Merlin L Robb, Robert J O'Connell, Nicos Karasavvas, Sandhya Vasan, Guido Ferrari, Georgia D Tomaras, RV305 study team
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Public Library of Science (PLoS) 2023-05-01
Saila:	PLoS Pathogens
Sarrera elektronikoa:	https://doi.org/10.1371/journal.ppat.1011359
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!